Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00215150 · ClinicalTrials.gov registry record · Phase 2
Geodon for the Treatment of Refractory Social Anxiety Disorder
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00215150 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 51 participants.
The verdict
NCT00215150, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment alone
Interventions
- DRUG Sertraline
- DRUG Ziprasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2004-11 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00215150
The ClinicalTrials.gov registry entry for NCT00215150 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sertraline is the first listed.
NCT00215150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00215150 about?
NCT00215150 is a clinical study titled "Geodon for the Treatment of Refractory Social Anxiety Disorder". The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment alone
What is the current status of trial NCT00215150?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2004-11. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00215150?
The interventions under investigation include: Sertraline (DRUG), Ziprasidone (DRUG).
Who is sponsoring clinical trial NCT00215150?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.